Advertisement

Heart Failure Reviews

, Volume 24, Issue 1, pp 109–114 | Cite as

The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis

  • Hidekatsu FukutaEmail author
  • Toshihiko Goto
  • Kazuaki Wakami
  • Takeshi Kamiya
  • Nobuyuki Ohte
Article

Abstract

Influenza infection is associated with increased risk for mortality and hospitalization in heart failure patients. Although there are no published randomized controlled trials examining the effect of influenza vaccination on clinical outcomes in heart failure patients, the effect has been examined in observational cohort studies. Nevertheless, results are inconsistent due partly to limited power with small sample sizes and use of different definitions of outcomes. We therefore aimed to conduct a systematic review and meta-analysis of the effect of influenza vaccination on mortality and hospitalization in heart failure patients. The search of electronic databases identified 6 observational cohort studies with 22,486 patients examining the effect of influenza vaccination on mortality and hospitalization in heart failure patients. Pooled analysis of confounder-adjusted hazard ratio showed that influenza vaccination was associated with reduced risk of mortality during 1-year follow-up (risk ratio [95% CI] = 0.76 [0.63–0.92], Pfix < 0.01) and during long-term (up to 4 years) follow-up (0.80 [0.71–0.90], Pfix < 0.001). Furthermore, influenza vaccination was associated with reduced risk of mortality during influenza season (risk ratio [95% CI] = 0.52 [0.39–0.69], Prandom < 0.001) and during non-influenza season (0.79 [0.69–0.90], Pfix < 0.001). Only a few studies reported the effect of influenza vaccination on hospitalization, which did not permit us to perform pooled analysis. In conclusion, our meta-analysis showed that influenza vaccination was associated with reduced risk of mortality in heart failure patients. Large-scale and adequately powered randomized controlled trials should be planned to confirm our observed potential survival benefit of influenza vaccination in these patients.

Keywords

Heart failure Influenza Vaccine Prognosis Meta-analysis 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Ohte has received lecture fees from Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Bayer GA, AstraZeneca plc, and Boehringer Ingelheim and grant support from Takeda Pharmaceutical Co. Ltd., Bayer GA, Daiichi Sankyo Co., Ltd., MSD, Novartis International AG, Boehringer Ingelheim, Astellas Pharma Inc., and Otsuka Pharmaceutical Co., Ltd. No other disclosures were reported.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Supplementary material

10741_2018_9736_MOESM1_ESM.docx (37 kb)
ESM 1 (DOCX 37 kb)

References

  1. 1.
    Roger VL (2013) Epidemiology of heart failure. Circ Res 113:646–659CrossRefGoogle Scholar
  2. 2.
    Alon D, Stein GY, Korenfeld R, Fuchs S (2013) Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One 8:e72476CrossRefGoogle Scholar
  3. 3.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy CW, Young JB (2008) Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 168:847–854CrossRefGoogle Scholar
  4. 4.
    Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ (2017) Can vaccinations improve heart failure outcomes?: contemporary data and future directions. JACC Heart Fail 5:194–203CrossRefGoogle Scholar
  5. 5.
    de Diego C, Vila-Corcoles A, Ochoa O, Rodriguez-Blanco T, Salsench E, Hospital I, Bejarano F, Del Puy MM, Fortin M, Canals M (2009) Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 30:209–216CrossRefGoogle Scholar
  6. 6.
    Liu IF, Huang CC, Chan WL, Huang PH, Chung CM, Lin SJ, Chen JW, Leu HB (2012) Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: a nationwide population-based study. Prev Med 54:431–433CrossRefGoogle Scholar
  7. 7.
    Kopel E, Klempfner R, Goldenberg I (2014) Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 16:264–270CrossRefGoogle Scholar
  8. 8.
    Wu WC, Jiang L, Friedmann PD, Trivedi A (2014) Association between process quality measures for heart failure and mortality among US veterans. Am Heart J 168:713–720CrossRefGoogle Scholar
  9. 9.
    Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD (2016) Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. JACC Heart Fail 4:152–158CrossRefGoogle Scholar
  10. 10.
    Blaya-Novakova V, Prado-Galbarro FJ, Sarria-Santamera A (2016) Effects of annual influenza vaccination on mortality in patients with heart failure. Eur J Pub Health 26:890–892CrossRefGoogle Scholar
  11. 11.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269CrossRefGoogle Scholar
  12. 12.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefGoogle Scholar
  13. 13.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefGoogle Scholar
  14. 14.
    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefGoogle Scholar
  15. 15.
    Gurfinkel EP, Leon dF, Mendiz O, Mautner B (2004) Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 25:25–31CrossRefGoogle Scholar
  16. 16.
    Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, Ksiezycka E, Przyluski J, Piotrowski W, Maczynska R, Ruzyllo W (2008) Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 29:1350–1358CrossRefGoogle Scholar
  17. 17.
    Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP (2013) Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 310:1711–1720CrossRefGoogle Scholar
  18. 18.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e327PubMedGoogle Scholar
  19. 19.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200CrossRefGoogle Scholar
  20. 20.
    Michalsen A, Konig G, Thimme W (1998) Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 80:437–441CrossRefGoogle Scholar
  21. 21.
    Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA, Ryden L (2000) Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102:611–616CrossRefGoogle Scholar
  22. 22.
    Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN (2010) HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16:e1–e194CrossRefGoogle Scholar
  23. 23.
    Vardeny O, Moran JJ, Sweitzer NK, Johnson MR, Hayney MS (2010) Decreased T-cell responses to influenza vaccination in patients with heart failure. Pharmacotherapy 30:10–16CrossRefGoogle Scholar
  24. 24.
    Van EA, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O (2013) Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. Eur J Heart Fail 15:560–564CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Core LaboratoryNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Cardio-Renal Medicine and HypertensionNagoya City University Graduate School of Medical SciencesNagoyaJapan
  3. 3.Department of Medical InnovationNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations